Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
October 25 2018 - 4:30PM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, will announce financial results for the
Third Quarter 2018 and provide a general business update before the
U.S. markets open on Tuesday, November 6, 2018. Following the
announcement, the company will host a live teleconference and
webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day.
The press release and the live webcast of the conference call
will be available in the investor section of Adaptimmune’s
corporate website at www.adaptimmune.com. An archive will be
available after the call at the same address.
To participate in the live conference call, please dial (833)
652-5917 (U.S.) or +1 (430) 775-1624 (International). After placing
the call, please ask to be joined into the Adaptimmune conference
call and provide the confirmation code (2458438).
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T‑cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, MAGE-A10, and
AFP across multiple solid tumor indications. The Company is
located in Philadelphia, USA and Oxfordshire,
U.K. For more information, please
visit http://www.adaptimmune.com.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on August 2, 2018, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:Media
Relations:Sébastien Desprez – VP, Communications and
Investor RelationsT: +44 1235 430 583M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2024 to May 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From May 2023 to May 2024